These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 14967070)

  • 1. Lung cancer: looking ahead in 2004.
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2004 Jan; 5(4):200. PubMed ID: 14967070
    [No Abstract]   [Full Text] [Related]  

  • 2. Tyrosine kinase signal transduction inhibitors. Clinical trials.
    Scagliotti GV
    Suppl Tumori; 2002; 1(4):S34-6. PubMed ID: 12415814
    [No Abstract]   [Full Text] [Related]  

  • 3. EGFR inhibition in NSCLC: the emerging role of cetuximab.
    Herbst RS
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S41-51. PubMed ID: 19780245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rational basis of using novel targeted biological agents in non-small cell lung cancer.
    Ciardiello F
    Suppl Tumori; 2002; 1(4):S31-3. PubMed ID: 12415813
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting the epidermal growth factor receptor a new strategy in cancer treatment.
    Gianni L; Grasselli G
    Suppl Tumori; 2002; 1(4):S60-1. PubMed ID: 12415824
    [No Abstract]   [Full Text] [Related]  

  • 6. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
    Friedrich MJ
    J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
    [No Abstract]   [Full Text] [Related]  

  • 7. [ZD1839].
    Nakagawa K
    Nihon Rinsho; 2002 May; 60 Suppl 5():378-83. PubMed ID: 12101693
    [No Abstract]   [Full Text] [Related]  

  • 8. Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC.
    Van Zandwijk N; Baas P
    Suppl Tumori; 2002; 1(4):S37-8. PubMed ID: 12415815
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
    Saba NF; Khuri FR; Shin DM
    Oncology (Williston Park); 2006 Feb; 20(2):153-61; discussion 162, 166, 169 passim. PubMed ID: 16562649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor mutations: a new insight.
    Belani CP
    Clin Lung Cancer; 2004 May; 5(6):328. PubMed ID: 15217529
    [No Abstract]   [Full Text] [Related]  

  • 11. Gefitinib (Iressa): a novel treatment for non-small cell lung cancer.
    Vansteenkiste J
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):5-17. PubMed ID: 14748652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Is it possible to treat bronchial carcinoma without chemotherapy?].
    Pujol JL
    Rev Mal Respir; 2006 Sep; 23(4 Pt 2):10S23-10S26. PubMed ID: 17127957
    [No Abstract]   [Full Text] [Related]  

  • 13. Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.
    Cho D; Kocher O; Lee JC; Tenen DG; Meyerson ML; Janne PA; Halmos B
    J Clin Oncol; 2005 Jan; 23(1):235-7. PubMed ID: 15625379
    [No Abstract]   [Full Text] [Related]  

  • 14. Gefitinib versus cetuximab in lung cancer: round one.
    Minna JD; Peyton MJ; Gazdar AF
    J Natl Cancer Inst; 2005 Aug; 97(16):1168-9. PubMed ID: 16106015
    [No Abstract]   [Full Text] [Related]  

  • 15. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
    Technol Eval Cent Assess Program Exec Summ; 2011 Mar; 25(6):1-5. PubMed ID: 21638942
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes.
    Baselga J
    J Clin Oncol; 2002 May; 20(9):2217-9. PubMed ID: 11980990
    [No Abstract]   [Full Text] [Related]  

  • 17. [Targeted therapies for lung cancer].
    Tamura K
    Rinsho Ketsueki; 2008 Aug; 49(8):616-21. PubMed ID: 18800610
    [No Abstract]   [Full Text] [Related]  

  • 18. Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer.
    Ho C; Davies A; Mack P; Gandara D
    Clin Lung Cancer; 2007 Jul; 8(7):420-4. PubMed ID: 17681094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer.
    Chang GC; Yang TY; Chen KC; Yin MC; Wang RC; Lin YC
    J Clin Oncol; 2004 Nov; 22(22):4646-8. PubMed ID: 15542815
    [No Abstract]   [Full Text] [Related]  

  • 20. Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors.
    Bar J; Onn A
    Clin Lung Cancer; 2012 Jul; 13(4):267-79. PubMed ID: 22154113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.